HealthPharma & Biotech

Shares of Savara plunge after disappointing Phase 3 lung disease study results

Patients given the treatment saw an improvement not statistically significant from the placebo

Savara is an Austin, Texas orphan lung disease pharmaceutical company

Savara Inc (NASDAQ:SVRA) stock plummeted after a Phase 3 trial of its treatment for an autoimmune lung disease failed to reach the desired results.

Molgradex, the company’s drug for Autoimmune Alveolar Pulmonary Proteinosis, was tested against a placebo and measured for improvement in the alveolar-arterial oxygen gradient, the ratio of oxygen concentration in the lungs and arteries.

Shares collapsed on the disappointing results, falling 75% to $2.59.

READ: Hemispherx treats first patient with cancer drug Ampligen in Phase 2 clinical trials

Patients given the treatment saw an improvement not statistically significant from the placebo.

That said, patient-reported outcomes and quality of life measurements did improve with treatment, which was considered a secondary endpoint of the study, known as IMPALA.

"Disappointingly, with the placebo effect stronger than anticipated, the study did not meet its primary endpoint,” CEO Rob Neville said. “We are preparing to meet with the FDA and [the European Medicines Agency] to discuss the results from this study and to determine our options to seek approval based on the current data, and potentially conduct an additional study incorporating the learnings from IMPALA."

Savara is an Austin, Texas orphan lung disease pharmaceutical company. 

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Savara

Price: 0.93 USD

Market: NASDAQ
Market Cap: $38.31 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



MJ Micro conference brings together public and private cannabis companies

MJ Link, a Subsidiary of Social Like Network (OTCQB: WDLF) CEO Kenn Tapp and President of MJ Micro Todd Markey sat down with Steve Darling from Proactive Vancouver at the MJ Micro Conference held in Los Angeles. Markey talked about the success of the conference and just how they picked the...

8 hours, 24 minutes ago

2 min read